Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO ...

Apple and Masimo are back in a California court this week for a bench trial that will see Masimo arguing that Apple illegally ...

Ladies and gentlemen, good afternoon, and welcome to ... we expect SET to kind of perform -- continue to perform in that range of long-term, that kind of 6% to 8% rainbow double-digit growth ...

The lawsuit resulted in five of Masimo’s claims being rejected, and a jury being unable to reach agreement on the rest. That will see a new trial held, at a date yet to be set. Masimo got its ...

Masimo (NASDAQ:MASI) is set to give its latest quarterly earnings report on Tuesday, 2024-11-05. Here's what investors need to know before the announcement. Analysts estimate that Masimo will ...

Masimo MASI2.20%increase; green up pointing triangle said Joe Kiani, who previously informed the board of his decision to resign as chief executive, has been terminated by the company. Kiani’s ...

Vanderbilt University Medical Center is launching Masimo Radius VSM™ advanced wireless patient-worn vital signs monitoring ...

According to a regulatory filing, following a review by outside counsel, on October 24, 2024, the Board of Directors of Masimo (MASI) adopted resolutions to terminate the employment of Masimo’s ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.

The modular, scalable monitoring platform offers a range of physiological measurements, including Masimo SET® pulse oximetry, measure-on-inflation noninvasive blood pressure, continuous ...